Apotex wins in Latisse®/bimatoprost

from the case Allergan v. Apotex



Apotex Inc., Apotex Corp., Sandoz, Inc., Hit-Tech
Pharmacal Co., Inc., Actavis, Inc., Watson Laboratories,
Inc., and Watson Pharma, Inc. (collectively “appellants”)
appeal from a final judgment of the U.S. District Court for
the Middle District of North Carolina finding that appellants
had infringed claims of U.S. Patent Nos. 7,388,029
(“’029 patent”) and 7,351,404 (“’404 patent”) and had
failed to establish they were invalid. For the reasons
stated below, we reverse the district court’s findings with
respect to the validity of each patent.